A Study of RE-021 in Patients With Focal Segmental Glomerulosclerosis

This study has been withdrawn prior to enrollment.
(Withdrawn and replaced with a revised study)
Information provided by (Responsible Party):
Retrophin, Inc.
ClinicalTrials.gov Identifier:
First received: June 13, 2012
Last updated: November 13, 2013
Last verified: November 2013

This is a study to investigate RE-021 in patients with focal segmental glomerulosclerosis (FSGS)

Condition Intervention
Primary Focal Segmental Glomerulosclerosis
Drug: RE-021

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: A Study of RE-021 in Patients With Focal Segmental Glomerulosclerosis

Resource links provided by NLM:

Further study details as provided by Retrophin, Inc.:

Primary Outcome Measures:
  • Evaluate change in albumin excretion rate (AER) from baseline

Enrollment: 0
Study Start Date: July 2013
Estimated Study Completion Date: August 2014
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: RE-021 Drug: RE-021


Ages Eligible for Study:   up to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Biopsy-proven primary FSGS (Primary FSGS confirmed by renal biopsy report OR documentation of a genetic mutation in a podocyte protein associated with the disease)

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01622738

United States, New York
NYU School of Medicine - Langone Medical Center
New York, New York, United States, 10016
Sponsors and Collaborators
Retrophin, Inc.
Principal Investigator: Howard Trachtman, M.D. NYU MEDICAL CENTER
  More Information

Additional Information:
No publications provided

Responsible Party: Retrophin, Inc.
ClinicalTrials.gov Identifier: NCT01622738     History of Changes
Other Study ID Numbers: RET-D-002
Study First Received: June 13, 2012
Last Updated: November 13, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Glomerulosclerosis, Focal Segmental
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on April 17, 2014